Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19 infections .
Description: Change in patient Arterial Oxygen Partial Pressure (PaO2)/Fractional Inspired Oxygen (FiO2) Ratio
Measure: Pulmonary Oxygenation Function Time: Up to 72 hoursDescription: Change in patient oxygenation
Measure: Pulmonary Compliance of Respiratory System (CRS) Time: Up to 96 hoursDescription: Change in the total number of patients that survived
Measure: Survival Time: 30 days and 60 daysDescription: Change in Hospital Utilization of ventilators (days)
Measure: Hospital Costs 1 Time: Out to 60 daysDescription: Change in score based on the calculation of the following medications used: dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 x adrenaline dose (µg/kg/min) + 100 x noradrenaline dose (µg/kg/min) + 10 x milrinone dose (µg/kg/min) + 10.000 x vasopressin dose (U/kg/min)
Measure: Cardiovascular Vasoactive-Inotropic Score (VIS) Time: Up to 96 hoursDescription: Change in Hospital Utilization of vasopressor medication (days without use)
Measure: Hospital Costs 2 Time: Out to 60 daysDescription: Change in Hospital Utilization of Intensive Care Unit (ICU) Hospital free days
Measure: Hospital Costs 3 Time: Out to 60 daysDescription: Change in Hospital Utilization of Renal Replacement Therapy (days on therapy)
Measure: Hospital Costs 4 Time: Out to 60 daysDescription: Change in Hospital Utilization (days hospitalized)
Measure: Hospital Costs 5 Time: Out to 60 daysDescription: Changes in inflammatory mediators detected by Immunoassay of Multianalyte Panel - MAP Laboratory Panel of 253 analytes.
Measure: Inflammatory mediators in blood Time: Out to 14 hoursDescription: Change in cytokine levels obtained from plasma and blood collected prior to and after filter. Analyte concentrations in ultrafiltrate and plasma, expressed in the same concentration units, will be aggregated as a ratio of ultrafiltrate concentration to plasma concentration to yield a unitless Sieving Coefficient (SC). SC is an index of membrane function.
Measure: Cytokine Sieving Effects Time: Out to 8 hoursDescription: Change in blood Ferritin (mg/mL)
Measure: Specific Blood Indicators 1 Time: Out to 14 hoursDescription: Change in blood Interleukin-6 (pg/mL)
Measure: Specific Blood Indicators 2 Time: Out to 14 hoursDescription: Change in blood C-reactive protein (CRP) (mg/L)
Measure: Specific Blood Indicators 3 Time: Out to 14 hoursDescription: Change in blood Lactate Dehydrogenase (LDH) (U/L)
Measure: Specific Blood Indicators 4 Time: Out to 14 hoursDescription: Change in blood D-dimer (mcg/L*FEU2)
Measure: Specific Blood Indicators 5 Time: Out to 14 hoursDescription: Change in blood White Blood Cell (WBC) count (%)
Measure: Specific Blood Indicators 6 Time: Out to 14 hoursDescription: Change in blood Neutrophil count (%)
Measure: Specific Blood Indicators 7 Time: Out to 14 hoursDescription: Change in blood lymphocyte count (%).
Measure: Specific Blood Indicators 8 Time: Out to 14 hoursDescription: Change in the duration of days of diagnosed HAI/ Sepsis infections
Measure: Hospital Acquired Infections (HAI) /Sepsis Time: 30 and 60 daysDescription: Duration without Respiratory Replacement Therapy (RRT), ventilator, and time to discharge
Measure: Composite Recovery Time: Up to 30 daysDescription: Survival without Respiratory Replacement Therapy (RRT), ventilator, or time to Long Term Care (LTC)
Measure: Composite Survival Time: 30 and 60 daysDescription: Survival with Respiratory Replacement Therapy (RRT), ventilator or in Long Term Care (LTC)
Measure: Composite Non-Recovery Time: Up to 60 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports